PHASQ stock plunges 99% in 2026: PhaseBio Pharmaceuticals bankruptcy aftermath

PHASQ stock has collapsed 99% as PhaseBio Pharmaceuticals navigates Chapter 11 bankruptcy proceedings. Trading on the PNK exchange in the United States, PHASQ stock now trades at USD 0.000001 per share, down from USD 0.0399 at its 52-week high. The clinical-stage biopharmaceutical company filed for bankruptcy in October 2022, leaving shareholders facing severe losses. This dramatic decline reflects the company’s inability to advance its cardiovascular drug pipeline, including lead candidate bentracimab (PB2452). Understanding PHASQ stock’s trajectory is critical for investors evaluating distressed biotech opportunities.

PHASQ Stock Price Collapse: Understanding the 99% Decline

PHASQ stock has experienced one of the most severe declines in biotech history, losing 99% of its value. The stock trades at USD 0.000001, representing a catastrophic drop from its 52-week high of USD 0.0399. Daily volume stands at just 2,500 shares, compared to an average of 22,310, indicating severely diminished liquidity. The previous close was USD 0.0001, showing continued downward pressure. This collapse stems directly from PhaseBio Pharmaceuticals’ October 2022 Chapter 11 bankruptcy filing, which wiped out equity value. Investors who held PHASQ stock through the bankruptcy face near-total losses, with recovery prospects extremely limited.

PhaseBio Pharmaceuticals’ Bankruptcy Impact on PHASQ Stock

PhaseBio Pharmaceuticals filed for Chapter 11 reorganization in the U.S. Bankruptcy Court for the District of Delaware on October 23, 2022. This decision marked the end of the company’s independent operations and triggered the collapse of PHASQ stock value. The bankruptcy eliminated shareholder equity, leaving common stock holders with minimal recovery prospects. The company’s clinical-stage pipeline, including bentracimab for antiplatelet reversal and PB1046 for pulmonary arterial hypertension, could not generate sufficient revenue to sustain operations. Based in Malvern, Pennsylvania, with 600 full-time employees at its peak, PhaseBio could not overcome development challenges and funding constraints that plague many biotech firms.

PHASQ Stock Fundamentals: Negative Metrics Across the Board

PHASQ stock exhibits deeply negative fundamental metrics that reflect the company’s distressed state. The earnings per share (EPS) stands at -2.14, indicating substantial losses. The price-to-earnings ratio is -15.72, a meaningless metric given negative earnings. Free cash flow per share is -1.70, showing the company burns cash rapidly. Operating cash flow per share is -1.61, confirming ongoing operational losses. The current ratio of 1.75 suggests some short-term liquidity, but this provides little comfort given bankruptcy status. Return on equity is near zero at 0.22%, while return on assets is deeply negative at -0.22%. These metrics confirm PHASQ stock represents a distressed asset with minimal fundamental support.

Meyka AI Analysis: PHASQ Stock Grade and Forecast

Meyka AI rates PHASQ stock with a score of 59.12 out of 100, assigning a C+ grade with a HOLD suggestion. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects the extreme distress of the company while acknowledging minimal recovery potential. Meyka AI’s forecast model projects PHASQ stock could stabilize near current levels, with limited upside given bankruptcy constraints. The forecast suggests minimal price appreciation from USD 0.000001, as reorganization outcomes remain highly uncertain. These grades and forecasts are model-based projections and not guarantees of future performance.

Healthcare Sector Context: PHASQ Stock Among Biotech Losers

PHASQ stock represents one of the worst performers in the Healthcare sector’s Biotechnology industry. While the broader biotech sector faces headwinds from rising interest rates and regulatory scrutiny, PHASQ stock’s collapse far exceeds typical sector declines. The company’s inability to advance clinical trials or secure funding partnerships distinguishes it from struggling peers. PhaseBio’s co-development agreement with SFJ Pharmaceuticals X, Ltd. for bentracimab could not prevent bankruptcy. The company’s three-year decline of -99.99997% dwarfs most biotech losses. PHASQ stock now trades as a penny stock on the PNK exchange, reflecting its status as a distressed asset with minimal institutional support.

PHASQ Stock Recovery Prospects: Limited Upside in Bankruptcy

Recovery prospects for PHASQ stock remain extremely limited given ongoing bankruptcy proceedings. Shareholders typically receive minimal or zero recovery in Chapter 11 cases, with creditors prioritized ahead of equity holders. The company’s intellectual property, including bentracimab and other drug candidates, may be acquired by other firms, but this would not benefit current PHASQ stock holders. The 52-week low of USD 0.000001 represents the floor for PHASQ stock, with downside risk to complete delisting. Any recovery would require successful asset sales or reorganization that preserves equity value, an unlikely scenario. Investors should treat PHASQ stock as a speculative distressed asset with minimal fundamental support or recovery catalysts.

Final Thoughts

PHASQ stock has become a cautionary tale in biotech investing, collapsing 99% following PhaseBio Pharmaceuticals’ October 2022 bankruptcy filing. Trading at USD 0.000001 on the PNK exchange, PHASQ stock now represents a distressed asset with minimal recovery prospects. The company’s inability to advance its cardiovascular drug pipeline, combined with funding constraints, forced Chapter 11 reorganization that eliminated shareholder value. Meyka AI’s C+ grade and HOLD rating reflect the extreme distress while acknowledging limited upside potential. Investors should avoid PHASQ stock unless willing to accept near-total loss risk. The company’s clinical-stage assets may eventually be acquired, but current shareholders face minimal recovery probability. This situation underscores the high-risk nature of clinical-stage biotech investments and the importance of diversification in healthcare portfolios.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.